Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, with an Extension to Explore Any Drug-Drug Interaction Potential with Methotrexate (Part 1), and in Patients with Rheumatoid Arthritis, with Preliminary Assessment of Efficacy in Patients (Part 2)

2023-510247-38-00 Protocol IA-14069_1b Human pharmacology (Phase I) - Other Ended

Start 7 Jun 2024 · End 15 Oct 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol IA-14069_1b

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 45
Countries 1
Sites 2

Rheumatoid arthritis

Key facts

Sponsor
Ilab Co. Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
7 Jun 2024 → 15 Oct 2025
Decision date (initial)
2024-05-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-510247-38-00
ClinicalTrials.gov
NCT05533372

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Rheumatoid arthritis

VersionLevelCodeTermSystem organ class
23.1 PT 10039073 Rheumatoid arthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ilab Co. Ltd.

Sponsor organisation
Ilab Co. Ltd.
Address
9-22 Pangyoro255beon-Gil, Bundang Bundang
City
Seongnam
Postcode
13486
Country
Korea, Republic of

Scientific contact point

Organisation
Ilab Co. Ltd.
Contact name
Taegwon Oh

Public contact point

Organisation
Ilab Co. Ltd.
Contact name
Taegwon Oh

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ended 35 2
Rest of world
United States
10

Investigational sites

Romania

2 sites · Ended
Spitalul Clinic Judetean De Urgenta Cluj
Ophthalmology Building, 1st floor, wards 33, 34, and 35, Strada Clinicilor 3-5, 400006, Cluj-Napoca
Arensia Clinics S.R.L.
ARENSIA Clinics S.R.L., 3rd floor-, and wards 1, 2, 3, 4, 5, 6 and 7, Intrarea Tudor Stefan 38-40, 011658, Bucharest

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2024-06-07 2025-10-15 2024-06-07 2025-09-11

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-07 Romania Acceptable with conditions
2024-05-20
2024-05-24
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-26 Romania No conclusion
2024-08-12
2024-08-14
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-18 Romania No conclusion
2024-08-12
2024-11-18
4 SUBSTANTIAL MODIFICATION SM-2 2025-01-31 Romania Acceptable
2025-03-17
2025-03-24
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-09-17 Romania Acceptable
2025-03-17
2025-09-17